News

The lack of a reflex response that was relieved temporarily after exercise, a phenomenon known as post-exercise facilitation, is an early sign of Lambert-Eaton myasthenic syndrome (LEMS), a case report suggests. The report described the case of a woman, 62, who had a neuroendocrine tumor in the gallbladder…

The rare case of a man with lung cancer complicated by two co-occurring cancer-associated syndromes — Lambert-Eaton myasthenic syndrome (LEMS) and syndrome of inappropriate antidiuretic hormone secretion (SIADH) — was described in a recent report. According to its scientists, only four other documented reports of LEMS and SIADH developing…

DyDo Pharma is seeking approval of Firdapse (amifampridine) to treat Lambert-Eaton myasthenic syndrome (LEMS) in Japan. A decision from Japan’s Pharmaceuticals and Medical Devices Agency is expected in September. DyDo’s application was submitted in collaboration with Catalyst Pharmaceuticals, which developed Firdapse. DyDo is leading the development…

The rare case of a man with Lambert-Eaton myasthenia syndrome (LEMS) that co-occurred with non-Hodgkin lymphoma, a type of immune cell cancer, was described in a recent report. “In this case report, we present the case of a 57-year-old male diagnosed with non-Hodgkin’s lymphoma (NHL) who developed LEMS, an…

The U.S. Patent and Trademark Office has sent a notice of allowance for two additional patents for Firdapse (amifampridine), Catalyst Pharmaceuticals’ approved therapy for Lambert-Eaton myasthenic syndrome (LEMS), for claims related to its bioavailability under fasting and fed dosing conditions. Catalyst, which has licensing rights in North…

The U.S. Food and Drug Administration (FDA) has agreed to review Catalyst Pharmaceuticals’ request to raise to 100 mg the maximum recommended daily dose of Firdapse (amifampridine), its approved treatment for Lambert-Eaton myasthenic syndrome (LEMS). Firdapse’s label allows for an 80 mg maximum daily dose…

When United Nations (UN) member states gathered recently to discuss advancing universal health coverage by 2030, a side event was also held that focused on universal coverage for people with rare disorders. The event, titled “A Blueprint for Leaving No One Behind,” was held in New York by…

In an elderly man, Lambert–Eaton myasthenic syndrome (LEMS) was complicated by overlapping symptoms of autoimmune encephalitis, a type of brain inflammation caused by self-reactive antibodies, according to a report from Japan. “When atypical symptoms occur in patients with LEMS, it is important to consider the possibility of concomitant autoimmune…

In the first documented case of its kind, spontaneous cancer regression was seen in a man in Japan with Lambert-Eaton myasthenic syndrome (LEMS) associated with lung cancer. Given that cancer-associated LEMS is thought to be triggered by the immune system attacking cancer cells, scientists believe such a LEMS-driving immune…

The National Organization for Rare Disorders (NORD) is now accepting applications from patient advocacy organizations — ones focused on supporting people with a rare disease, such as Lambert-Eaton myasthenic syndrome (LEMS) — to implement two new patient registries on its IAMRARE platform. To amplify its set of…